San Francisco, CA – June 6, 2016
Who: Patrick Lucy, Chief Business Officer, Pfenex
What: Overview of Pfenex at BIO2016
When: Tuesday, June 7 at 3:00 p.m. Pacific
Where: Moscone Center, San Francisco, CA, Room 4
Why: Pfenex Chief Business Officer, Patrick Lucy, will present an overview of Pfenex and its product pipeline, including biosimilar candidates to BETASERON® (interferon beta-1b) for the treatment of Multiple Sclerosis and NEULASTA® (peg-filgrastim) for the treatment of neutropenia; as well as therapeutic equivalent to FORTEO® (teriparatide) for the treatment of osteoporosis; and next-generation recombinant Protective Antigen anthrax vaccine. Learn how the Company’s proprietary expression technology—the Pfenex Expression Technology®—enables it to create expression strains to make non-glycosylated proteins at high quality, and low costs.
Pfenex Inc. (NYSE: PFNX) is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value, and difficult-to-manufacture, proteins. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis® (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfenex Expression Technology® platform to build a pipeline of product candidates under development including other biosimilars, as well as vaccines, generics, and next-generation biologics. For additional information, visit Pfenex.com and connect with us on Twitter @Pfenex.
Note: All trademarks mentioned herein are property of their respective owners.
Media contact: Michelle Ragsdale, Pfenex | Direct (858) 352-4391 | email@example.com